ABLYNX ANNOUNCES 2016 FULL YEAR RESULTS

REGULATED INFORMATION

Significant progress in key pre-clinical and clinical development programmes

Conference call and webcast today at 4pm CET/10am ET

GHENT, Belgium, 23 February 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its financial results for the year ended 31^st December 2016, which have been prepared in accordance with IFRS as adopted by the European Union, business highlights year-to-date and the outlook for the remainder of the year.
           

• Total revenues of €85.2 million (+10%); cash position of €235.4 million, strengthened by the successful private placement of new shares via an accelerated book building procedure that raised €74.2 million
   
• Net cash burn^[1] of €72.2 million, in line with the previously guided range of €65-75 million
   
• R&D highlights:
  • strong recruitment of patients with acquired thrombotic thrombocytopenic purpura (aTTP) in the Phase III HERCULES study with caplacizumab
  • successful completion of two Phase IIb studies in rheumatoid arthritis (RA) with vobarilizumab in approximately 600 patients
  • completed recruitment of 312 patients with systemic lupus erythematosus (SLE) in Phase II study of vobarilizumab 
  • positive topline results for the anti-respiratory syncytial virus (RSV) Nanobody® (ALX-0171) in 53 hospitalised infants
  • three Phase I trials started in partnered programmes
  • initiated 19 new discovery programmes both proprietary and as part of collaborations
  • extended one pharmaceutical partnership and received four milestone payments from partners
     
• Post-period highlights:
  • initiated the global Phase IIb RESPIRE study of ALX-0171 in 180 infants hospitalised as a result of a RSV infection
  • encouraging Phase Ib data in the Merck KGaA partnered anti-IL-17A/F programme in psoriasis
  • submitted an application in Europe for regulatory approval of caplacizumab for the treatment of aTTP